Viridian Therapeutics Inc (NASDAQ: VRDN) kicked off on Tuesday, down -0.30% from the previous trading day ,before settling in for the closing price of $16.90. Over the past 52 weeks, VRDN has traded in a range of $10.93-$30.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -12.71%. While this was happening, its average annual earnings per share was recorded 15.57%. With a float of $55.85 million, this company’s outstanding shares have now reached $62.77 million.
Let’s determine the extent of company efficiency that accounts for 96 employees.
Viridian Therapeutics Inc (VRDN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 11.02%, while institutional ownership is 90.44%. The most recent insider transaction that took place on Jan 22 ’24, was worth 9,999,990. In this transaction Director of this company bought 476,190 shares at a rate of $21.00, taking the stock ownership to the 1,839,954 shares. Before that another transaction happened on Jun 16 ’23, when Company’s Chief Legal Officer sold 27 for $28.35, making the entire transaction worth $765. This insider now owns 29,971 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$1.35 earnings per share (EPS), lower than consensus estimate (set at -$1) by -$0.35. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.57% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Take a look at Viridian Therapeutics Inc’s (VRDN) current performance indicators. Last quarter, stock had a quick ratio of 18.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3411.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.32, a number that is poised to hit -1.09 in the next quarter and is forecasted to reach -4.53 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Looking closely at Viridian Therapeutics Inc (NASDAQ: VRDN), its last 5-days average volume was 0.63 million, which is a drop from its year-to-date volume of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 41.40%. Additionally, its Average True Range was 0.98.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 25.77%, which indicates a significant decrease from 33.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.82% in the past 14 days, which was lower than the 66.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.30, while its 200-day Moving Average is $18.20. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $17.28. Second resistance stands at $17.70. The third major resistance level sits at $18.08. If the price goes on to break the first support level at $16.48, it is likely to go to the next support level at $16.10. Should the price break the second support level, the third support level stands at $15.68.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
The company with the Market Capitalisation of 1.06 billion has total of 62,768K Shares Outstanding. Its annual sales at the moment are 310 K in contrast with the sum of -237,730 K annual income. Company’s last quarter sales were recorded 70 K and last quarter income was -66,860 K.
